Literature DB >> 6910482

Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit.

R C Wiggins, P C Giclas, P M Henson.   

Abstract

Rabbit plasma kallikrein incubated with rabbit C5 resulted in the generation of chemotactic and secretagogue activity for rabbit neutrophils. This effect on C5 appeared to be due to kallikrein itself and not to a contaminating enzyme, because it could be inhibited by anti-kallikrein IgG or by soybean trypsin inhibitor to the same extent the kinin generation by the same kallikrein preparation was inhibited by these agents. The chemotactic response was consistent with the generation of a C5a-like peptide from C5 because the effect could be partially inhibited by carboxypeptidase N and was related to the generation of a small (approximately 14,000 mol wt) fragment of C5. No direct chemotactic response was detectable for kallikrein, activated Hageman factor, high-molecular weight kininogen, or intact C5. Incubation of Kallikrein, high-molecular weight kininogen, and Hageman factor together, so that activation of all three proteins occurred, did not results in the generation of detectable chemotactic activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6910482      PMCID: PMC2186194          DOI: 10.1084/jem.153.6.1391

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.

Authors:  A S Weiss; J I Gallin; A P Kaplan
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Activation of Hageman factor by collagen.

Authors:  G D Wilner; H L Nossel; E C LeRoy
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

4.  The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

5.  A chemotactic factor for mononuclear leukocytes.

Authors:  R Snyderman; H S Shin; M H Hausman
Journal:  Proc Soc Exp Biol Med       Date:  1971-11

6.  The kinin system of human plasma. V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa).

Authors:  M J Soltay; H Z Movat; A H Ozge-Anwar
Journal:  Proc Soc Exp Biol Med       Date:  1971-12

7.  A neutrophil chemotactic factor from human C'5.

Authors:  P A Ward; L J Newman
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

8.  Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin.

Authors:  S Niewiarowski; E Bańkowski; I Rogowicka
Journal:  Thromb Diath Haemorrh       Date:  1965-11-15

9.  Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors.

Authors:  E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

10.  Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates.

Authors:  R Snyderman; J K Phillips; S E Mergenhagen
Journal:  J Exp Med       Date:  1971-11-01       Impact factor: 14.307

View more
  32 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

Review 2.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

3.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

4.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

Review 5.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

Review 6.  Complement inhibition as a proposed neuroprotective strategy following cardiac arrest.

Authors:  Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Peter A DeRosa; Andrew F Ducruet; E Sander Connolly
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

7.  Generation of C5a by phagocytic cells.

Authors:  Markus Huber-Lang; Ellen M Younkin; J Vidya Sarma; Niels Riedemann; Stephanie R McGuire; Kristina T Lu; Robin Kunkel; John G Younger; Firas S Zetoune; Peter A Ward
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

8.  Genetically determined resistance to listeriosis is associated with increased accumulation of inflammatory neutrophils and macrophages which have enhanced listericidal activity.

Authors:  C J Czuprynski; B P Canono; P M Henson; P A Campbell
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

9.  Human plasma kallikrein releases neutrophil elastase during blood coagulation.

Authors:  Y T Wachtfogel; U Kucich; H L James; C F Scott; M Schapira; M Zimmerman; A B Cohen; R W Colman
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  Purified human plasma kallikrein aggregates human blood neutrophils.

Authors:  M Schapira; E Despland; C F Scott; L A Boxer; R W Colman
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.